BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Prognosis
18 results:

  • 1. Cut-off Analysis of hla-a and HLA-B/C Expression as a Potential Prognosticator of Favorable Survival in Patients With Metastatic breast cancer.
    Stefanovic S; Wirtz R; Sütterlin M; Karic U; Schneeweiss A; Deutsch TM; Wallwiener M
    Anticancer Res; 2023 Apr; 43(4):1449-1454. PubMed ID: 36974778
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Conditional Survival of Patients With Extracranial Oligometastatic Treated With Stereotactic Body Radiation Therapy: An International Consortium Study.
    Chen H; Badellino S; Biswas T; Dagan R; Erler D; Foote M; Poon I; Redmond KJ; Ricardi U; Sahgal A; Louie AV
    Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):902-909. PubMed ID: 35753554
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Expression pattern of m
    He X; Tan L; Ni J; Shen G
    Cancer Gene Ther; 2021 Apr; 28(3-4):188-196. PubMed ID: 32759989
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers.
    Tsang JY; Ho CS; Ni YB; Shao Y; Poon IK; Chan SK; Cheung SY; Shea KH; Marabi M; Tse GM
    Cancer Immunol Immunother; 2020 May; 69(5):799-811. PubMed ID: 32055918
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Sinn BV; Weber KE; Schmitt WD; Fasching PA; Symmans WF; Blohmer JU; Karn T; Taube ET; Klauschen F; Marmé F; Schem C; Stickeler E; Ataseven B; Huober J; von Minckwitz G; Seliger B; Denkert C; Loibl S
    Breast Cancer Res; 2019 Dec; 21(1):142. PubMed ID: 31829264
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL Cytotoxicity Using a Novel Identified hla-a2-restricted MAGE-A11 Peptide.
    Zhang J; Sang M; Gu L; Liu F; Li W; Yin D; Wu Y; Liu S; Huang W; Shan B
    J Immunother; 2017; 40(6):211-220. PubMed ID: 28486273
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
    Chung YR; Kim HJ; Jang MH; Park SY
    Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer.
    Kijima T; Hazama S; Tsunedomi R; Tanaka H; Takenouchi H; Kanekiyo S; Inoue Y; Nakashima M; Iida M; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yamamoto S; Yoshino S; Okuno K; Nagano H
    Oncol Rep; 2017 Jan; 37(1):23-30. PubMed ID: 27878288
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
    Suzuki N; Hazama S; Iguchi H; Uesugi K; Tanaka H; Hirakawa K; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Shimizu R; Hayashi H; Sakata K; Takenouchi H; Matsui H; Shindo Y; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Nakamura Y; Oka M; Nagano H
    Cancer Sci; 2017 Jan; 108(1):73-80. PubMed ID: 27783849
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive breast cancer Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Aug; 144(2):278-88. PubMed ID: 26185313
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes.
    Győrffy B; Bottai G; Fleischer T; Munkácsy G; Budczies J; Paladini L; Børresen-Dale AL; Kristensen VN; Santarpia L
    Int J Cancer; 2016 Jan; 138(1):87-97. PubMed ID: 26174627
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.
    Visus C; Ito D; Dhir R; Szczepanski MJ; Chang YJ; Latimer JJ; Grant SG; DeLeo AB
    Cancer Immunol Immunother; 2011 Jul; 60(7):919-29. PubMed ID: 21409596
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Distant metastases in ovarian carcinoma.
    Cormio G; Rossi C; Cazzolla A; Resta L; Loverro G; Greco P; Selvaggi L
    Int J Gynecol Cancer; 2003; 13(2):125-9. PubMed ID: 12657111
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.
    Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
    Anticancer Res; 1997; 17(4A):2815-8. PubMed ID: 9252721
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer.
    Concha A; Esteban F; Cabrera T; Ruiz-Cabello F; Garrido F
    Semin Cancer Biol; 1991 Feb; 2(1):47-54. PubMed ID: 1912518
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. MHC expression on human tumors--its relevance for local tumor growth and metastasis.
    Garrido F; Ruiz-Cabello F
    Semin Cancer Biol; 1991 Feb; 2(1):3-10. PubMed ID: 1912516
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.
    Wintzer HO; Benzing M; von Kleist S
    Br J Cancer; 1990 Aug; 62(2):289-95. PubMed ID: 2201398
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Association of HLA with breast cancer and its ER status].
    Song ST
    Zhonghua Zhong Liu Za Zhi; 1989 Jan; 11(1):19-21. PubMed ID: 2789129
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.